Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Cash & Equivalents: 2023-2025

Historic Cash & Equivalents for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $301.6 million.

  • Zenas BioPharma's Cash & Equivalents fell 16.23% to $301.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $301.6 million, marking a year-over-year decrease of 16.23%. This contributed to the annual value of $319.7 million for FY2024, which is 462.36% up from last year.
  • Zenas BioPharma's Cash & Equivalents amounted to $301.6 million in Q3 2025, which was up 9.71% from $274.9 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Cash & Equivalents high stood at $360.0 million for Q3 2024, and its period low was $37.2 million during Q1 2024.
  • Its 3-year average for Cash & Equivalents is $213.4 million, with a median of $274.9 million in 2025.
  • The largest annual percentage gain for Zenas BioPharma's Cash & Equivalents in the last 5 years was 745.67% (2025), contrasted with its biggest fall of 16.23% (2025).
  • Over the past 3 years, Zenas BioPharma's Cash & Equivalents (Quarterly) stood at $56.9 million in 2023, then surged by 462.36% to $319.7 million in 2024, then decreased by 16.23% to $301.6 million in 2025.
  • Its Cash & Equivalents stands at $301.6 million for Q3 2025, versus $274.9 million for Q2 2025 and $314.2 million for Q1 2025.